Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.
about
Molecular Imaging of Prostate CancerPositron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.Update on advances in molecular PET in urological oncologyDiagnostic value of 18F-fluorodeoxyglucose uptake parameters to differentiate rheumatoid arthritis from other types of arthritis.(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer.Prognostic Utility of PET in Prostate Cancer.[(18)F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments.Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.(18)F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer.PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.Circulating tumour cells-monitoring treatment response in prostate cancer.Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers.Inhibition of Lipid Oxidation Increases Glucose Metabolism and Enhances 2-Deoxy-2-[(18)F]Fluoro-D-Glucose Uptake in Prostate Cancer Mouse Xenografts.Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters.Is There Use for FDG-PET in Prostate Cancer?Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy.Advances in Imaging in Prostate and Bladder Cancer.Malignant lipogenesis defined by 11C-acetate PET/CT predicts prostate cancer-specific survival in patients with biochemical relapse after prostatectomy.A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.Does focal incidental 18F-FDG PET/CT uptake in the prostate have significance?FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy.Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.Advances in prostate-specific membrane antigen PET of prostate cancer.From gametogenesis and stem cells to cancer: common metabolic themes.
P2860
Q33620520-DC47DDAD-DE0B-4403-A8DB-600F8632F036Q33625371-1028E615-515D-4694-A18E-B6ACF1A809BBQ33625389-84F9F8B3-3136-4445-8C82-39EA84C130B7Q33833615-5216016D-B595-433B-A3B2-854CF69A9D43Q34987693-FFEF7C15-336C-4246-8999-05A05450ABBEQ35244433-07582850-60A6-44A3-B2B8-F52AF2488275Q35806005-8FE7A8F7-2F0C-4EC0-A168-1B76F0FE74D3Q36407003-70F89888-3422-4C17-AFE5-4FC9E9576FA3Q36502692-2E13F6BA-78D2-4E11-A6B7-B86A592B9F9DQ37390670-E2F9BFE7-2EAA-4BD5-826A-1340ED3E6B88Q37702328-539D90BF-7AD8-4034-9A14-54CD71E2F7C9Q38211361-83794AC9-81EA-4E4B-A4B7-4C45E4830A8DQ38920663-EE37BA25-DB35-45FB-BB37-CDDB6994B674Q38922956-A81E505C-1D5E-46FE-9CC7-5159F6B6DEB3Q38983205-46934ED8-E9C6-407E-A153-34CB1C329472Q39003083-AB2224FB-EA84-44CF-8389-2BDAF6627B24Q39143177-94D95C36-6A8A-4E3D-998A-1546216DA2EAQ39441078-7C8A385B-3E08-40F6-B595-FDA9F5E7D970Q40661091-F7D0B69E-7687-471B-96E4-34F153B677DFQ40735810-7A65AB96-06ED-4C84-A4F9-61CE42747315Q41161118-018BE809-3226-4F64-AF10-71BC6D166096Q41690642-8052F7F2-FD3D-4832-B6D3-42143ADB3B7FQ42117913-00975DEB-7781-4DA1-BF30-2D5B60F973E1Q48205881-B5FD9016-027E-45DE-80E3-922E2513A1B3Q49713199-26A1AC4F-133E-4F7D-B255-74A91C3C85CCQ51069058-9AD017C8-C1FD-440E-AAC3-A5B2F24FD3F0
P2860
Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Baseline 18F-FDG PET/CT parame ...... nt metastatic prostate cancer.
@en
Baseline 18F-FDG PET/CT parame ...... nt metastatic prostate cancer.
@nl
type
label
Baseline 18F-FDG PET/CT parame ...... nt metastatic prostate cancer.
@en
Baseline 18F-FDG PET/CT parame ...... nt metastatic prostate cancer.
@nl
prefLabel
Baseline 18F-FDG PET/CT parame ...... nt metastatic prostate cancer.
@en
Baseline 18F-FDG PET/CT parame ...... nt metastatic prostate cancer.
@nl
P2093
P2860
P1476
Baseline 18F-FDG PET/CT parame ...... ant metastatic prostate cancer
@en
P2093
Bhushan Desai
Hossein Jadvar
Jacek K Pinski
Lingyun Ji
Peter S Conti
Susan G Groshen
Tanya B Dorff
P2860
P304
P356
10.2967/JNUMED.112.114116
P407
P577
2013-06-19T00:00:00Z